Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Glutamate and schizophrenia: beyond the dopamine hypothesis.

Coyle JT.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84. Epub 2006 Jun 14. Review.

PMID:
16773445
2.

Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.

Coyle JT, Tsai G, Goff D.

Ann N Y Acad Sci. 2003 Nov;1003:318-27. Review.

PMID:
14684455
3.

Glutamatergic mechanisms in schizophrenia.

Tsai G, Coyle JT.

Annu Rev Pharmacol Toxicol. 2002;42:165-79. Review.

PMID:
11807169
4.

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

Goff DC, Coyle JT.

Am J Psychiatry. 2001 Sep;158(9):1367-77. Review.

PMID:
11532718
5.

Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Coyle JT.

Neurotox Res. 2006 Dec;10(3-4):221-33. Review.

PMID:
17197372
6.

[Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].

Hashimoto K, Iyo M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2002 Feb;22(1):3-13. Review. Japanese.

PMID:
11917507
7.

Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.

Stone JM, Morrison PD, Pilowsky LS.

J Psychopharmacol. 2007 Jun;21(4):440-52. Epub 2007 Jan 26. Review.

PMID:
17259207
8.

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.

PMID:
16719816
9.

Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G.

Handb Exp Pharmacol. 2012;(213):267-95. doi: 10.1007/978-3-642-25758-2_10. Review.

10.

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.

Coyle JT, Tsai G.

Psychopharmacology (Berl). 2004 Jun;174(1):32-8. Epub 2003 Nov 25. Review.

PMID:
15205876
11.
12.
13.

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.

Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D.

Schizophr Bull. 2012 Sep;38(5):958-66. doi: 10.1093/schbul/sbs069. Review.

14.

The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.

Balu DT, Coyle JT.

Curr Opin Pharmacol. 2015 Feb;20:109-15. doi: 10.1016/j.coph.2014.12.004. Epub 2014 Dec 23. Review.

15.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039
16.

Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?

Singer P, Dubroqua S, Yee BK.

Curr Pharm Des. 2015;21(26):3771-87. Review.

PMID:
26205290
17.

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Shim SS, Hammonds MD, Kee BS.

Eur Arch Psychiatry Clin Neurosci. 2008 Feb;258(1):16-27. Epub 2007 Sep 27. Review.

PMID:
17901997
18.

The GABA-glutamate connection in schizophrenia: which is the proximate cause?

Coyle JT.

Biochem Pharmacol. 2004 Oct 15;68(8):1507-14. Review.

PMID:
15451393
19.

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.

Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A.

Clin Ther. 2005;27 Suppl A:S16-24. Review.

PMID:
16198197
20.

Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.

Laruelle M, Kegeles LS, Abi-Dargham A.

Ann N Y Acad Sci. 2003 Nov;1003:138-58. Review.

PMID:
14684442

Supplemental Content

Support Center